Day: January 15, 2025

ST. GALLEN, Switzerland, Jan. 15, 2025 (GLOBE NEWSWIRE) — Sportradar Group AG (NASDAQ: SRAD) (“Sportradar” or the “Company”), a leading global sports technology company, today announced that it will host an Investor Day in New York City on Tuesday, April 1, 2025. Carsten Koerl, Chief Executive Officer, Craig Felenstein, Chief Financial Officer, and senior business leaders will present the business strategy, growth drivers and financial outlook. The event will conclude with a Q&A session with the Company’s senior leadership. Presentations will commence at 9:00 am eastern time and conclude at approximately 12:00 pm. To register your virtual attendance and view the live presentation, please use this link, investorday2025.sportradar.com. Due to limited capacity, in-person attendance is by invitation only to institutional investors...

The Company’s oncology aPKCi inhibitor is a novel, first in class drug candidate WARRINGTON, Pa., Jan. 15, 2025 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced the issuance of a patent in Japan for “Inhibitors of atypical protein kinase C (aPKCi) and their use in treating hedgehog pathway-dependent cancers.” The patent number is 7603605 and expires in 2040. The aPKCi inhibitor platform is a novel, potential high-potency, specific, drug candidate with applications in oncology, particularly in hedgehog pathway-dependent cancers. Such cancers include basal cell carcinoma, medulloblastoma, rhabdomyosarcoma, small cell lung cancer and other malignant...

PARIS, Jan. 15, 2025 (GLOBE NEWSWIRE) — Constellium SE (NYSE: CSTM) (“Constellium” or the “Company”) announced today that, while it remains a foreign private issuer under applicable rules, it intends to voluntarily file its SEC reports on U.S. domestic issuer forms. As a result, beginning in 2025, Constellium will voluntarily file annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K. In addition, Constellium expects to voluntarily file the proxy statement for its 2025 annual general meeting with the SEC and provide certain disclosures in accordance with the requirements of Schedule 14A under the Exchange Act (utilizing Form 8-K). Jean-Marc Germain, Constellium’s Chief Executive Officer said, “I am very excited to make this announcement today, as I believe it marks...

MARKHAM, Ontario, Jan. 15, 2025 (GLOBE NEWSWIRE) — Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.04 per common share of the Company (the “Common Share”) for the month of January 2025, which is payable on February 14, 2025 to shareholders of record at the close of business on January 31, 2025. This dividend is designated as an “eligible dividend” within the meaning of the Income Tax Act (Canada). About Extendicare Extendicare is a leading provider of care and services for seniors across Canada, operating under the Extendicare, ParaMed, Extendicare Assist, and SGP Purchasing Network brands. We are committed to delivering quality care to meet the needs of a growing seniors’ population, inspired by our mission to provide people with the care they need, wherever they...

Only U.S.-Listed ETF Providing Pure-Play Exposure to Silver Miners and Physical Silver Silver Miners ETF Adds to Sprott’s Expanding ETF Suite TORONTO, Jan. 15, 2025 (GLOBE NEWSWIRE) — Sprott Asset Management LP (“Sprott Asset Management”) today announced the launch of the Sprott Silver Miners & Physical Silver ETF (Nasdaq: SLVR) (the “ETF” or “SLVR”), the only1 ETF focused on providing pure-play2 exposure to silver miners and physical silver, an undervalued precious metal with evolving industrial and technological uses. The ETF is the most recent addition to Sprott Asset Management’s suite of ETFs and draws on its extensive experience in the precious metals and critical materials space. “Silver is one of the world’s best-known precious metals, and we believe it’s positioned to perform well in today’s market. In addition, demand...

Asbjørn Eskild has been appointed as new CEO of Jøtul Group, a global supplier of stoves and fireplaces with its main production facilities in Norway, Poland and United States. Jøtul’s CEO in the past 8 years, Nils Agnar Brunborg, will be retiring. Asbjørn has extensive experience in the CEO role of international companies, most recently as the CEO of Topro Group, a producer of mobility aids. His previous roles include that of CEO of the listed company Handicare Group AB and of Hamax AS. “The Board of Directors would like to thank Nils Agnar very much for his leadership of Jøtul during the past years. The period has been very demanding, with restructuring of the production and distribution footprint in a very volatile market. On behalf of the entire organization, the Board would like to thank Nils Agnar for his extraordinary contributions...

1,200 bed health system selects eValutor’s pre-bill code audit technology to improve coding accuracy ATLANTA, Jan. 15, 2025 (GLOBE NEWSWIRE) — Streamline Health Solutions, Inc. (NASDAQ: STRM), a leading provider of solutions that enable healthcare providers to improve financial performance, announced that it has signed a new contract for the use of eValuator with Deaconess Health System, a 1,200 bed Indiana-based health system. Deaconess selected Streamline Health’s eValuator solution to optimize its pre-bill coding accuracy and financial outcomes. “We were seeking automation to assist with improving coding and billing workflows as well as accuracy within the mid-revenue cycle. eValuator’s unique capabilities stood apart and best fit our organizational priorities” stated Rebecca Conen, VP/Chief Revenue Cycle Officer, Healthcare...

Blarcamesine potential novel oral treatment to target upstream Alzheimer’s disease pathology through autophagy enhancement Impairment of autophagy precedes both amyloid beta and tau tangles, and therefore anticipates the neurodegenerative process in Alzheimer’s disease NEW YORK, Jan. 15, 2025 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that The Journal of Prevention of Alzheimer’s Disease (JPAD) has published peer-reviewed detailed results from the Phase IIb/III study evaluating...